Innovation shapes the future

Cancer immunotherapy based
on viral vectors

Explore our platform

We combine the use of viral vectors that have been engineered and optimized to express artificial genes encoding high-dimensional strings of human neoantigens, with state-of-the art bioinformatics for cancer neoantigen prediction. The unprecedented neoantigen-encoding capacity of our platform and its ability to efficiently and consistently express large numbers of neoantigens, provides significant advantages over other strategies, offering a unique approach to the potentiation of human anti-tumor responses.

NOUS-209

An off-the-shelf cancer immunotherapy for dMMR/MSI tumors

Clinical

Expanded access policy to be found here

About NOUS-209

NOUS-209 is an investigational off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency (dMMR) and microsatellite instability (MSI). These tumors are characterized by unique markers known as frameshift peptide (FSP) neoantigens, which are unique to cancerous cells and absent in healthy cells. NOUS-209 comprises two proprietary viral vectors able to deliver 209 shared FSP neoantigens and train the immune system to recognize and attack cancerous and precancerous cells before tumors can develop.

Phase 1b/2 data demonstrated the safety of NOUS-209 and its ability to stimulate potent immune responses in LS carriers1,2, supporting its advancement into a registration-enabling trial in cancer interception. NOUS-209 is also being studied in Phase 2 studies in combination with pembrolizumab in a difficult-to-treat patient population of advanced dMMR and/or MSI-H metastatic CRC (mCRC) patients refractory to anti-PD-1 therapy3 and in first-line treatment of advanced dMMR and/or MSI-H mCRC. Data from the successfully completed Phase 1b trial were published in Science Translational Medicine4.

About Lynch Syndrome

Lynch Syndrome (LS) is a common inherited condition that significantly increases a person’s risk of developing cancer over their lifetime, especially colorectal cancer (CRC) (up to 50% risk, compared to 2% for general population), endometrial cancer (up to 50% risk, compared to 1-2% for general population) and urothelial cancer (up to 25% risk, compared to 1-2% for general population)5,6,7,8. LS also elevates the risk of developing other cancers including biliary tract, brain, duodenal, gastric, Muir-Torre spectrum, ovarian, prostate, pancreatic and small bowel cancer. LS is caused by inherited mutations in specific genes responsible for repairing DNA, leading to the buildup of harmful genetic errors that can accumulate, triggering the development of tumors. Currently, managing LS is limited to frequent screenings such as colonoscopy to catch cancer early, but is not shown to reduce cancer incidence9, and elective surgery, which is invasive, expensive, and negatively impacts quality of life. As a pioneering approach to cancer interception, Nouscom’s investigational immunotherapy, NOUS-209, is designed to train the immune system to recognize and stop cancer before it develops.

About Cancer Interception

Cancer interception is an innovative approach that aims to stop cancer in its earliest stages before tumors fully develop and spread. Unlike traditional therapies that target established cancers, interception strategies harness advancements in immuno-oncology that can train the immune system to recognize and eliminate precancerous and cancerous cells. This approach is particularly relevant for those with high-risk genetic conditions such as LS who have high predisposition to developing MSI-associated cancers.

References

  1. D’Alise, AM. et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial. Nature Medicine (2026); DOI: 10.1038/s41591-025-04182-9.
  2. Willis et al, Cancer Res (2025) 85 (8_Supplement_1): 6427.
  3. Abstract is available on the ESMO website, here.
  4. D’Alise et al., Science Translational Medicine, 2022.
  5. Dominguez-Valentin et al., Genetics in Medicine, 2020.
  6. Dominguez-Valentin et al., The Lancet, 2023.
  7. Strafford, Reviews in Obstetrics & Gynecology, 2012.
  8. Richters et al., World Journal of Urology, 2020.
  9. Ahadova et al., International Journal of Cancer 2020.

NOUS-PEV

Personalised cancer vaccine

Clinical

NOUS-PEV is a personalised cancer vaccine based on patient-specific neoantigens sourced from individual patient tumor mutanomes. The technology may be applied to any cancer indication where a tumor biopsy is available that is suitable for next-generation sequencing (NGS).

Nouscom has developed a robust and rapid manufacturing process from patient biopsy to vaccine release. This process allows for the assembly of strings of up to 60 unique patient mutanome-specific neoantigens selected and prioritized using the VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection) proprietary algorithm (1) within a single vector and the production of small patient-specific quantities of personalized vaccine.

NOUS-PEV successfully completed Phase 1b trial in metastatic melanoma patients(2)

NOUS-PEV demonstrated 90% success in manufacturing feasibility, it was shown to be safe, well tolerated and highly immunogenic, inducing potent and long lasting neoantigen-specific CD4 and CD8 T cell responses. Biomarker analysis demonstrated neoantigen-specific increased T cell migration and infiltration in tumors in patients with durable clinical responses (Bechter et al, Cancer Res (2023) 83 (8_Supplement): LB196)

References

  1. Leonie et al., Vaccines, 2021.
  2. D’Alise et al., Clin Cancer Research, 2024.
error: Content is protected !!!